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Abstract
Introduction: An online survey was conducted to characterize current infection management practices in Italian
intensive care units (ICUs), including the antibacterial and antifungal drug regimens prescribed for various types of
infections.
Methods: During February and March 2011, all 450 ICUs in public hospitals in Italy were invited to take part in an
online survey. The questionnaire focused on ICU characteristics, methods used to prevent, diagnose, and treat
infections, and antimicrobials prescribing policies. The frequency of each reported practice was calculated as a
percentage of the total number of units answering the question. The overall response rate to the questionnaire
was 38.8% (175 of the 450 ICUs contacted) with homogeneous distribution across the country and in terms of unit
type.
Results: Eighty-eight percent of the responding facilities performed periodical surveillance cultures on all patients.
In 71% of patients, cultures were also collected on admission. Endotracheal/bronchial aspirates were the most
frequently cultured specimens at both time points. Two-thirds of the responding units had never performed
screening cultures for methicillin-resistant Staphylococcus aureus. Around 67% of the ICUs reported the use of
antimicrobial de-escalation strategies during the treatment phase. In general, the use of empirical antimicrobial
drug regimens was appropriate. Although the rationale for the choice was not always clearly documented, the use
of a combination therapy was preferred over antibiotic monotherapy. The preferred first-line agents for invasive
candidiasis were fluconazole and an echinocandin (64% and 25%, respectively). Two-thirds of the ICUs monitored
vancomycin serum levels and administered it by continuous infusion in 86% of cases. For certain antibiotics,
reported doses were too low to ensure effective treatment of severe infections in critically ill patients; conversely,
inappropriately high doses were administered for certain antifungal drugs.
Conclusions: Although infection control policies and management practices are generally appropriate in Italian
ICUs, certain aspects, such as the extensive use of multidrug empirical regimens and the inappropriate
antimicrobial dosing, deserve careful management and closer investigation.
Introduction
Drug prescribing patterns and clinical practices differ
from country to country, but variation has also been
observed among and within medical specialties. The dif-
ferences are probably related to the needs of different
patient populations, but they also reflect culture-specific
and individual attitudes and forms of decision making
among physicians [1]. Among developed countries, for
example, Italy has one of the highest rates of antibiotic
use [2]. Throughout the world, community use of these
drugs appears to be significantly conditioned by patients’
demand and other social factors [1,3]. These type of
influences should be virtually nonexistent in intensive
care units (ICUs), where antimicrobial therapy is usually
prescribed empirically on the basis of limited evidence
[4,5]. When compared with general medical wards, ICUs
displays higher rates of antimicrobial use because their
patients are at higher risk for severe nosocomial infec-
tions [6,7]. It has been estimated that over 50% of all cri-
tically ill patients will receive at least one antibiotic
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during their ICU stay, in most cases for pneumonia
[8-10]. Widespread, often inappropriate, use of antimi-
crobials can favor the emergence of resistances [10,11]
and increase the occurrence of treatment failure, toxicity,
mortality rates as well as the rise in the costs of care
among critically ill patients [10,12].
The aim of the present study was to characterize the
current infection management practices in Italian ICUs,
including the characterization of the antibacterial and
antifungal drug regimens prescribed for various types of
infections and the collection of evidence-based informa-
tion support in the intensive care setting. We believe
that the educational intervention programs carried out
in Italy over the last few years by local professional asso-
ciations have improved the infection control policies, the
management practices, and the prescribing patterns in
ICUs.
Materials and methods
Institutional review board approval was waived for this
email-based survey since it did not involve collection of
data on individual patients. The survey questionnaire was
prepared by a panel of experts in the fields of intensive
care, infectious diseases, pharmacology, and microbiology
and endorsed by the Società Italiana di Anestesia Analge-
sia Rianimazione e Terapia Intensiva (SIAARTI, Italian
Society of Anesthesia and Intensive Care) and organized
in different sections. Section I focused on the ICU’s char-
acteristics (for example, location, number of beds, level of
care, type of unit/hospital). Section II contained questions
(mostly multiple-choice) on the approaches used to diag-
nose and treat infections (for example, use and character-
istics of surveillance cultures, screening procedures) and
infection management practices (for example, consultation
of infectious disease specialists, access to antimicrobial
susceptibility test, prescribing policies for antibiotics and
antifungal drugs).
During the months of February and March 2011, the
SIAARTI sent emails to all physicians working in the 450
ICUs located in public hospitals in Italy, inviting them to
participate in the survey. The email explained the pur-
pose of the survey, the information handling practices,
and provided instructions for online completion of the
questionnaire. Each ICU director who accepted the invi-
tation was given password-controlled access to the survey
and was responsible for collecting all the information
from the physicians working in the unit to ultimately fill
in one questionnaire reflecting the overall opinion and
practices. Responses submitted between 30 April and 2
June 2011 were collected blindly into a central database
and analyzed.
Submitted questionnaires were excluded from the ana-
lysis only if Section I had not been completed. Failure to
answer one or more questions in Section II was not a
cause for exclusion. In Section II, the frequency of each
reported practice was calculated as a percentage of the
total number of units that answered the question
regarding that practice.
Results and discussion
Characteristics of participating ICUs
As summarized in Table 1, 175 of the 450 ICUs
responded to the questionnaires, and they all met the
inclusion criteria for data analysis (overall response rate:
38.8%). Seventy-five (43%) participating units were
located in northern Italy, 56 (32%) in central Italy, and
44 (25%) in southern regions. Most were located in
small (< 500 beds, 54%) or medium-sized (500 to 1000
beds, 30%) hospitals. Sixty-three (36%) were at teaching
hospitals. Eight-four percent were polyvalent ICUs, 13%
were surgical units, and other unit types accounted for
the remaining 3%. Most units (n = 163, 93%) contained
four to twelve beds. The overall number of admissions
per year varied from 80 to 1600, although in 63% of the
units the range was much narrower (100 to 400 per
year). The average ICU stay reported by respondents
ranged from one to fifteen days (mean eight days).
Infection control and management practices
Responses to infection control policies are summarized
in Tables 2, 3 and 4. Table 1 shows responses to ques-
tions regarding practices and resources used for the
Table 1 Sample characteristics of the ICU center
respondents.
Response rate 175/450 (38.8%)
Geographical distribution of ICU respondents
Northern Italy 75/175 (43%)
Central Italy 56/175 (32%)
Southern Italy 44/175 (25%)
Type of hospital
Teaching hospital 63/175 (36%)
Non-teaching hospital 112/175 (64%)
Hospital size
< 500 beds 85/175 (49%)
500-1000 beds 51/175 (29%)
1000-1500 beds 15/175 (8%)
< 1500 beds 24/175 (14%)
Type of ICU
Surgical 28/175 (16%)
Mixed (Medical/surgical) 147/175 (84%)
Number of ICU beds
1-6 77/175 (44%)
7-10 58/175 (33%)
11-18 33/175 (19%)
19-50 7/175 (4%)
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diagnosis, prevention, and management of infections,
which were answered by 146 to 162 of the 450 ICUs
contacted (response rate from 32% to 36%). Information
on routine empirical drug regimens used for specific
types of infections is shown in Tables 1 and 2 (response
rate from 32% to 38%). Table 3 shows how major anti-
bacterial and antifungal drugs were prescribed in terms
of doses, schedules, and methods of administration
(response rate from 20% to 33%). The number, types,
and location of the 175 units that took part in our sur-
vey are quite representative of the 450 ICUs that are
present in our country. The characteristics of the parti-
cipating units are also comparable to those documented
in the annual report of the Italian Group for the Evalua-
tion of Interventions in Intensive Care [13].
Practices and resources used for the diagnosis,
prevention, and management of infections
Although the importance of surveillance cultures for
detecting carriers of drug-resistant microorganisms,
improving nosocomial infection control, and guiding
empirical antimicrobial treatment in ICUs has been
documented [14,15], there are conflicting opinions that
routine surveillance cultures are indicated in critically ill
patients [16].
In our study, we found that 88% of the participating
units periodically performed surveillance cultures on all
patients, and in 71% of cases the cultures were also col-
lected on admission (Table 2). Endotracheal and bron-
chial aspirates were the most frequently cultured
specimens at both time points (92% and 90% of the units,
Table 2 Infection control and management practices in participating ICUs.
Practices Use - number (%)a
Surveillance cultures
○ on ICU admission 104/146 (71)
○ after ICU admission 128/146 (88)
Regular reports on antimicrobial resistance profiles of organisms isolated in the hospital 66/151 (41)
Automatic lab alerts when high-risk isolates are recoveredb 88/149 (59)
Nasal-swab screening for MRSA and decolonization when cultures are positive
○ Yes 24/151 (16)
○ No 103/151 (68)
○ In selected cases 24/151 (16)
Quantitative cultures of tracheobronchial secretions 108/156 (69)
Samples cultured to diagnose pneumonia
○ endotracheal aspirate 79/162 (49)
○ bronchoalveolar lavage fluid 68/162 (42)
○ protected-specimen brush 15/162 (9)
Routine use of the Candida colonization index 44/148 (30)
Use of the procalcitonin assay 100/152 (66)
Consultation of infectious disease specialists for infection management
○ Routinely 16/149 (11)
○ In selected cases 82/149 (55)
○ Rarely 36/149 (24)
○ No 15/149 (10)
Use of antibiotic combinations for first-line empirical treatment of specific infections
○ Community-acquired peritonitis 92/162 (57)
○ Early-onset ventilator-associated pneumonia (VAP) 107/162 (66)
○ Late-onset ventilator-associated pneumonia (VAP) 142/162 (88)
○ Community-acquired pneumonia (CAP) 113/162 (70)
○ Hospital-acquired pneumonia (HAP) 128/162 (79)
○ Health-care-associated pneumonia (HCAP) 138/162 (85)
○ Post-surgical peritonitis 133/162 (82)
○ Catheter-related bacteremia 107/162 (66)
○ Purulent meningitis 120/162 (74)
Therapy de-escalation when culture results are back 109/162 (67)
aDenominators represent the number of ICUs that answered the specific question; bhigh-risk isolates include MRSA, vancomycin-resistant enterococci, extended-
spectrum beta-lactamase-producing gram-negative bacilli, Candida spp., and so on). MRSA, methicillin-resistant Staphylococcus aureus.
Bassetti et al. Critical Care 2012, 16:R221
http://ccforum.com/content/16/6/R221
Page 3 of 10
respectively), which reflects a common concern among
Italian intensivists of prevention and prompt detection of
pneumonia. Regarding methicillin-resistant Staphylococ-
cus aureus (MRSA) surveillance, although there are stu-
dies to support the use of active surveillance for high-risk
patients [17,18], there is not sufficient evidence to justify
the mandatory use of this control measure [19]. Screen-
ing programs for MRSA colonization are expensive and,
for certain authors, of dubious utility. Universal screening
of large populations is not cost-effective, whereas tar-
geted screening of high-risk populations may deserve
additional study [20]. In our survey, two-thirds of the
responding units never tested for MRSA colonization.
This finding was consistent with the percentages of units
that reported to collect nasal swabs at the time of the
admission (46%) and after ICU admission (22%).
Although the potential role of Candida colonization
index for early detection of candidemia remains contro-
versial, two recent Italian reports support the value of
this tool [21,22]. In the survey, we observed that very few
units used the Candida colonization index during the
patients’ admission assessment (3%), and fewer than 20%
made regular use of the index after admission.
Over half of the participating sample (88 ICUs) received
automatic alerts when multidrug-resistant (MDR) or senti-
nel microorganisms were isolated. The majority of the
units were located in large and/or university hospitals in
northern or central Italy. The geographic distribution of
the hospitals that provided this service reflects regional
rather than national rules. Access to information on local
patterns of drug susceptibility was reported only in around
40% of the participating units. In roughly half of these
cases (33/66), the data were updated every six (33%)
or twelve (24%) months. Only three of the 66 ICUs men-
tioned (4.3%) had access to weekly updates. In our opi-
nion, these reports need to be issued at least once a
month, even if no MDR microorganisms have been iso-
lated, to increase physicians’ awareness of the local micro-
bial epidemiology. This seems particularly important in
light of the low number [16/149 (11)] of units that regu-
larly consulted an infectious disease specialist for advice
on antimicrobial use (Table 2). Two-thirds of the respond-
ing units reported the use of the procalcitonin assay.
Although procalcitonin seems to be a valuable predictor of
bacterial infections and an effective tool for reducing
unnecessary antibiotic use [23,24], its universal use in criti-
cally ill patients might have negative consequences [25,26].
Around 67% of the centers reported using de-escalation
strategies during antibiotic treatment. (In this case - and
others - the possibility of discrepancies between self-per-
ceived and actual behaviors cannot be excluded). Although
a recent Cochrane review found insufficient evidence to
recommend for or against antimicrobial de-escalation in
adults with a diagnosis of sepsis [27], this strategy appears
theoretically correct and capable of promoting therapeutic
appropriateness.
Empirical antimicrobial regimens
It is complex to comment on the appropriate use of
empirical antibiotic therapy given the wide variation of
Table 3 Antimicrobials most commonly used for empirical treatment of specific infections.
Infection/Drugs Frequency
number (%)a
Infection/Drugs Frequency
number (%)a
Early VAP (<5 days) Suspected catheter-related bacteremia
Piperacillin/tazobactam
Levofloxacin
Ceftriaxone
37/146 (25)
25/146 (17)
19/146 (13)
Vancomycin
Piperacillin/tazobactam
Meropenem
70/171 (41)
21/171 (12)
15/171 (9)
Late VAP (≥5 days) Suspected candidemia and/or invasive
Piperacillin/tazobactam
Meropenem
Ceftazidime
50/142 (35)
23/142 (16)
17/142 (12)
candidiasis
Fluconazole
Caspofungin
Voriconazole
97/151 (64)
32/151 (21)
9/151 (6%)
Community-acquired pneumonia Community-acquired peritonitis
Ceftriaxone
Levofloxacin
Amoxicillin/clavulanic acid
42/156 (27)
31/156 (20)
23/156 (15)
Piperacillin/tazobactam
Ampicillin/sulbactam
Cefotaxime
37/161 (23)
26/161 (16)
16/161 (10)
Hospital-acquired pneumonia Postoperative peritonitis
Piperacillin/tazobactam
Levofloxacin
Ceftriaxone
51/171 (30)
26/171 (15)
22/171 (13)
Piperacillin/tazobactam
Meropenem
Ertapenem
63/165 (38)
46/165 (28)
8/165 (5)
Health-care-acquired pneumonia Purulent meningitis
Piperacillin/tazobactam
Meropenem
Ceftazidime
39/143 (27)
24/143 (17)
13/143 (9)
Ceftriaxone
Linezolid
Cefotaxime
111/156 (71)
6/156 (4)
6/156 (4)
aDenominators represent the number of ICUs that answered the specific question. VAP, ventilator-associated pneumonia.
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Table 4 Most frequently used doses and schedules of antibiotic and antifungal drugs.
Drug/Administration Frequency
Number (%)a
Drug/Administration Frequency
Number (%)a
Vancomycin Ceftazidime
TDD: 2 g 104/142 (73) TDD: 6 g 89/141 (63)
Infusion: Continuous 122/142 (86) 3 g 20/141 (14)
Other: TDM 94/142 (66) Infusion: Continuous 68/141 (48)
Schedule: 3 doses/day 64/141 (45)
Teicoplanin Ceftriaxone
TDD: 400 mg 43/110 (39) TDD: 2 g 72/141 (51)
800 mg 32/110 (29) 4 g 45/141 (32)
Loading dose 86/90 (96) Schedule: 2 doses/day 78/141 (55)
Once daily 64/141 (45)
Piperacillin/tazobactam Cefepime
TDD: 18.0 g 61/148 (41) TDD: 6 g 51/141 (36)
13.5 g 41/148 (28) 4 g 28/141 (20)
Infusion: Intermittent 61/148 (41) Schedule: 3 doses/day 75/141 (53)
Continuous 55/148 (37) 2 doses/day 66/141 (47)
Prolonged (3-4 hours) 33/148 (22)
Meropenem Levofloxacinb
TDD: 3 g 62/138 (45) TDD: 1000 mg 81/139 (58)
6 g 26/138 (19) 750 mg 33/139 (24)
Infusion: Prolonged intermittent 65/138 (47) Schedule: 2 doses/day 90/139 (65)
Intermittent infusion 55/138 (40) Once daily 49/139 (35)
Continuous infusion 18/138 (13)
Imipenem Ciprofloxacinb
TDD: 2 g 66/135 (49) TDD: 1200 mg 61/138 (44)
3 g 28/135 (21) 800 mg 44/138 (32)
Schedule: 4 doses/day 99/135 (73) Schedule: 2 doses/day 70/138 (51)
3 doses/day 36/135 (27) 3 doses/day 68/138 (49)
Amikacin Fluconazole
TDD: 1 g 65/120 (54) TDD: 400 mg 77/137 (56)
1.5 g 13/120 (11) 800 mg 25/137 (18)
Schedule: Once daily 106/120 (88) Schedule: Once daily 104/137 (76)
2 doses/day 33/137 (24)
Loading dose 114/137 (83)
Gentamicin Voriconazole
TDD: 240 mg 35/120 (29) TDD: 8 mg/kg 56/137 (41)
160 mg 18/120 (15) 4 mg/kg 27/137 (20)
Schedule: Once a day 106/120 (88) Loading dose 125/137 (91)
Daptomycin Anidulafungin
TDD: 6 mg/kg 70/137 (51) TDD: 100 mg 94/124 (76)
8 mg/kg 29/137 (21) Loading dose 119/124 (96)
Linezolid Caspofungin
TDD: 1200 mg 128/132 (97) TDD: 50 mg 114/127 (90)
Infusion: Intermittent 111/132 (84) Loading dose 126/127 (99)
Tigecycline Micafungin
TDD: 100 mg 130/134 (97) TDD: 100 mg 105/128 (82)
Schedule: 2 doses/day 133/134 (99)
Loading dose 131/134 (98)
Colistin Amphotericin B
Intravenous TDD:
TDD: 6,000,000 IU 29/107(27) Liposomal
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resistance amongst different ICUs. However, the empiri-
cal regimens used in Italian ICUs to treat the most com-
mon infections appear - on the whole - appropriate, as
summarized by Table 3. It is noteworthy, however, that
more than half the participating units (57% to 88%)
used drug combinations rather than monotherapy for all
types of infection (Table 2) and, particularly, in cases of
pneumonia and postoperative peritonitis. Several origi-
nal reports and systematic reviews have raised questions
regarding the benefits of combination therapy (which
generally includes at least one beta-lactam antibiotic) for
serious bacterial infections in immunocompetent and
immunocompromised patients [28-30].
The frequent use of vancomycin for suspected catheter-
related bloodstream infections (41%) cannot be considered
inappropriate. Nevertheless, increasing vancomycin mini-
mum inhibitory concentrations (MICs) - recently defined
as MIC creep - have indeed been documented in S. aureus
isolates, but the impact of vancomycin MICs on outcomes
is still being debated [31]. The rationale for treating these
infections with piperacillin-tazobactam (reported in up to
12% of the ICUs) is questionable, since over 80% of these
infections are caused by Staphylococcus spp [32].
The preferred drugs reported for community-acquired
and postoperative peritonitis were beta-lactams (Table 3).
It is worth noting that in 50% of the participating units
piperacillin/tazobactam, which has itself an excellent
antianaereobic coverage, were used in association with
another antianaerobic drug, metronidazole. In numerous
studies, this type of redundant coverage has failed to
improve clinical outcomes, and it is also associated with
adverse effects and with selection of resistant strains [33].
The preferred first-line drug for invasive candidiasis
was fluconazole (64%), followed by echinocandins (25%).
Several consensus statements have been published on
the treatment of candidemia and invasive candidiasis.
The Infectious Diseases Society of America recommends
fluconazole as a single antifungal agent or an echinocan-
din-based therapy [34]. Therefore, in 2011, the use of
fluconazole was justified for stable patients, and echino-
candins were also a reasonable choice in adults.
Inadequate or delayed antifungal therapy has signifi-
cantly been linked to increased mortality [35], thus it is
virtually impossible to reliably predict the nature or
antimicrobial susceptibility of the causative Candida.
For these reasons, starting an empirical treatment with
fluconazole may have been considered inappropriate by
many Italian clinicians.
Dosing, schedules, and administration
The data presented in Table 4 provide a picture of how
antibiotics and antifungals are being administered in Ita-
lian ICUs. This is an important point since many of the
pathophysiological changes associated with severe acute
illness or sepsis (for example, increased capillary perme-
ability, third spacing, increased volume of distribution,
impaired renal and/or liver function) can affect antimi-
crobial pharmacokinetics (PK), especially those of drugs
that are excreted renally (for example, beta-lactams,
aminoglycosides, glycopeptides). Administration of these
drugs to severely ill patients at dosages defined in stu-
dies conducted in healthy volunteers often produces
suboptimal serum and tissue concentrations [36]. The
method of administration is equally important. Beta-lac-
tams, for example, are time-dependent antibiotics, and a
time above MIC of 80% to 100% is required for maxi-
mum activity. Consequently, they are often administered
via continuous or extended (3 to 4 h) infusion, an
approach that improves efficacy and may also reduce
the risk of inducing resistance [37].
In most units (132/148 - 89%), daily doses of piperacil-
lin-tazobactam ranged from 13.5 to 18 g, and more than
half the units (59%) infused the drugs over an interval
longer than 3 to 4 hours. Compared with intravenous
bolus delivery, extended infusion of this drug combina-
tion was recently shown to reduce mortality and shorten
hospital stays in ICU patients with Pseudomonas aerugi-
nosa infections [38]. Around 60% of the reporting units
gave meropenem as a continuous or extended infusion.
In critically ill patients at high risk for infections caused
by resistant strains of gram-negative bacteria (P. aerugi-
nosa, Acinetobacter), these approaches are more likely to
achieve the optimal pharmacodynamic (PD) target [39].
Several studies have emphasized the value of area under
the curve (AUC)/MIC ratios for predicting the efficacy of
glycopeptide-based regimens. The most commonly used
Table 4 Most frequently used doses and schedules of antibiotic and antifungal drugs. (Continued)
9,000,000 IU 27/107 (25) 3 mg/kg 61/127 (48)
Schedule: 3 times/day 65/107 (61) 5 mg/kg 48/127 (38)
Loading dose 48/107 (45) Lipid complex
Aerosol 5 mg/kg 54/101 (53)
TDD: 3,000,000 IU 36/107 (34) 3 mg/kg 29/101 (29)
Schedule: 3 times/day 61/107 (57)
aDenominators represent the number of ICUs that answered the specific question, blevofloxacin and ciprofloxacin are the only fluoroquinolones available in Italy.
TDD, total daily dose (intravenous unless otherwise stated); TDM, therapeutic drug monitoring.
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daily doses of teicoplanin were 6 mg/kg and 12 mg/kg
(corresponding to total daily doses of 400 and 800 mg,
respectively) and almost all units (96%) administered a
loading dose of this drug, which is important in ICU
patients to ensure rapid achievement of therapeutically
effective concentrations. Therapeutic drug monitoring
(TDM) is strongly recommended during vancomycin ther-
apy to optimize drug exposure and prevent toxicity [40].
Two-thirds of the ICUs monitored blood levels of vanco-
mycin, which was usually administered as a continuous
infusion (86%) (Table 3). However, three-quarters of the
units used standard daily dosages (2 grams) that are prob-
ably too low for critically ill patients. A recent PK/PD ana-
lysis of data for 191 ICU patients found that with standard
vancomycin dosages the recommended AUC 0 to 24/MIC
breakpoint for S. aureus is rarely achieved unless the
patient has renal failure or is over 65 years of age. Other-
wise, the daily dose needs to exceed 3 grams. This study
also emphasized the need to consider agents other than
vancomycin when methicillin-resistant or glycopeptide-
intermediate S. aureus strains are involved [41].
For the aminoglycosides, which are concentration-
dependent antibiotics, the efficacy target seems to be a
maximum serum drug concentration (Cmax)/MIC ratio
of 10 to 12 [42]. A single daily administration of 5 to
7 mg/kg of gentamicin is currently recommended, and a
similar approach can be used with amikacin (15 to
20 mg/kg/day) [43]. It is important to recall that serum
levels of aminoglycosides vary widely in critically ill
patients, and increased volumes of distribution may
result in suboptimal peak levels [44]. Almost all the par-
ticipating units gave aminoglycosides once daily, but in
light of the above findings, the most frequently reported
doses (15 mg/kg/day and 3 to 5 mg/kg/day for amikacin
and gentamicin, respectively) are probably too low to
reach the optimal PK-PD target. In contrast, levofloxacin
and ciprofloxacin (the only fluoroquinolones available in
Italy) were generally used at maximum recommended
daily doses: levofloxacin 1000 mg (58%) in two doses
or 750 mg (25%) in a single daily dose; ciprofloxacin
1200 mg (44%) or 800 mg (32%) in two to three doses.
These regimens should produce an AUC/MIC ratio of
about 125, which correlates with good microbiological
and clinical outcomes in critically ill patients [45].
Colistin has recently re-emerged as a last-resort treat-
ment for MDR gram-negative bacterial infections. In
several PK-PD studies, its effects have proved to be con-
centration-dependent, and AUC/MIC and Cmax/MIC
ratios are probably the factors correlated with outcome
[46,47]. Around half the participating centers appear to
be using this drug according to the more recent litera-
ture in terms of daily doses (6 to 9 million IUs in 52%
of the cases) and after the administration of a loading
dose (45%) (Table 4).
Almost all ICUs administered a fixed dose of tigecy-
cline (100 mg loading dose followed by 50 mg every
12 h). Regarding daptomycin, preliminary evidence sug-
gests that doses exceeding 6 mg/kg/day may be asso-
ciated with more favorable outcomes [48]. Around 21%
of the ICUs reported daptomycin doses exceeding the
approved range (4 to 6 mg/kg/day).
Analysis of antifungal drug-prescribing practices
revealed that most ICUs used appropriate daily and
loading doses of both the azoles and echinocandins.
However, in 38% of the participating units, liposomal
amphotericin B was administered at a daily dose of
5 mg/kg despite clear evidence that doses above 3 mg/
kg/day do not have an increased efficacy in the treat-
ment of invasive fungal infections [49]. Furthermore,
roughly 20% of the units reported using fluconazole at a
daily dose of 12 mg/kg. This is a much higher dose than
the one recommended by standard guidelines, and even
when it is administered empirically in a critically ill
patient with unexplained fever and a high risk for inva-
sive candidiasis, it is unjustified and inappropriate [34].
TDM is indicated for many azoles (especially itracona-
zole, voriconazole, and posaconazole) [50]. Blood levels of
antifungal drugs are characterized by broad, unpredictable
variability related to multiple factors, including patients’
age, genetic background, compliance, gastrointestinal
function, use of co-medications, and liver and/or renal
dysfunction [45]. Negative outcomes are associated with
both antifungal underdosing (treatment failure) and over-
dosing (toxicity) [50]. Unfortunately, real-time measure-
ment of antifungal drug blood levels is not routinely
available, which may explain why voriconazole TDM was
not mentioned by our ICUs.
Our study has several limitations. First of all, our ques-
tionnaire did not by any means explore all aspects of
infection control. Second, although the sample surveyed
is representative of the Italian ICUs, the overall response
rate was less than 40%, with even lower response rates in
certain questions. This raises the possibility of a selection
bias toward ICUs that are more concerned with the effi-
cacy of their infection management policies and proce-
dures. Third, all of our data reflect self-reported behavior
that may or may not coincide with actual practices, and
physicians often tend to overestimate their use of recom-
mended practices (tests, procedures, drug regimens) [51].
Given the last two considerations, certain problematic
areas in the ICU setting may have escaped our detection.
On the other hand, however, those that did emerge are
likely to be realistic, and they may even underestimate
more serious and widespread issues.
Our survey indicates that certain resources and tools
for infection control are being underused in Italian
ICUs, including MRSA screening and updated reports
on local microbial epidemiology. As for antimicrobial
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drug therapy, prescribing practices were generally
appropriate, but certain aspects deserve closer investiga-
tion, above all the widespread preference for multidrug
empirical regimens, which in some cases seemed diffi-
cult to justify. Furthermore, certain antibiotics were
reportedly used at doses unlikely to achieve PK/PD tar-
gets in critically ill patients, whereas inappropriately
high doses were reported for certain antifungal drugs.
There is little evidence that practices of this type can be
corrected by guidelines, restrictive formularies, or other
administrative measures, probably because they usually
stem from a lack of information [52]. Our findings will
hopefully serve to stimulate Italian ICUs to critically
review their own infection management policies with
the aim of reinforcing the strong points and correcting
practices likely to be less effective.
Conclusions
In this study, although infection control policies and
management practices are generally appropriate in Ita-
lian ICUs, certain aspects, such as the extensive use of
multidrug empirical regimens and the inappropriate
antimicrobial dosing, deserve careful management and
closer investigation.
Key messages
• Considering the number, types, and locations of
the 175 units that took part in our survey, the sam-
ple is quite representative of Italy’s 450 ICUs.
• The majority of the participating units periodically
performed surveillance cultures on and after admission.
• Empirical antimicrobial drug regimens for specific
infections were generally appropriate. Combination
therapy was preferred over monotherapy (sometimes
without clear justification), and around 70% of the
centers reported using de-escalation strategies during
the treatment phase.
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